Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Magazine"

Comorbidity of alcohol dependence and depression: severities and singularities of therapy

A.E.Nikolishin , V.V.Shein , A.E. Konoreva, A.O.Kibitov, A.G. Gofman
V.P. Serbsky Federal Medical Research Center of Psychiatry and Addiction, Ministry of Health of the Russian Federation

Резюме. Depression occurs in 25–40 % of patients with alcohol dependence (AD). Despite the effectiveness of pharmacotherapy with separately existing AD and depression, the use of drugs in comorbid pathology has not been adequately tested and is being actively studied. The variability of the effect of pharmacological agents on 45–75 % is due to genetic factors. SSRIs remain drugs of the first line and in the treatment of patients with comorbid AD and depression. When combined with drugs that block the desire for alcohol, SSRIs increase the overall effectiveness of pharmacotherapy. Pharmacotherapy should be conducted within the framework of complex treatment, which must necessarily include psychotherapy. The use of the pharmacogenetic approach can provide new opportunities for improving the selection and tolerability of pharmacotherapy and improving the quality of life of patients. To search for scientific and medical information, we used PubMed and eLIBRARY.RU electronic libraries with the use of filters and keywords. Data from systematic reviews, meta-analyzes and randomized clinical trials over the past 20 years were reviewed.

References: 
  • 1. Anthenelli R.M., Schuckit M.A. Affective and anxiety disorders and alcohol and drug dependence: Diagnosis and treatment // J Addict Dis. – 1993. – Vol. 12, No. 3. – P. 73–87.
  • 2. Davis L.L., Rush J.A., Wisniewski S.R., Rice K., Cassano P., Jewell M.E., Biggs M.M., Shores-Wilson K., Balasubramani G.K., Husain M.M., Quitkin F.M., McGrath P.J. Substance use disorder comorbidity in major depressive disorder: an exploratory analysis of the Sequenced Treatment Alternatives to Relieve Depression cohort // Compr Psychiatry. – 2005. – Vol. 46, No. 2. – P. 81–89.
  • 3. Kessler R.C., Nelson C.B., McGonagle K.A. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization // Am J Orthopsychiatry. – 1996. –Vol. 66, No. 1. – P. 17–31.
  • 4. Gofman A.G. Klinicheskaya narkologiya. — 2-e izd. — M.: OOO «Izdatel'stvo “Meditsinskoe informatsionnoe agentstvo”», 2017. — S. 122–163.
  • 5. Anthenelli R.M. Focus on: comorbid mental health disorders // Alcohol Res Health. – 2010. – Vol. 33, No. 1–2. – P. 109–117.
  • 6. Sher L., Stanley B.H., Harkavy-Friedman J.M., Carballo J.J., Arendt M., Brent D.A., Sperling D., Lizardi D., Mann J.J., Oquendo M.A. Depressed patients with co-occurring alcohol use disorders: a unique patient population // J Clin Psychiatry. – 2008. – Vol. 69, No. 6. – P. 907–915.
  • 7. Weissman M. M., Roger C. B., Canino G. J., Faravelli C., Greenwald S., Hwu H. G., Joyce P. R., Karam E. G., Lee C. K., Lellouch J., Lépine J. P., Newman S. C., Rubio-Stipec M., Wells J. E., Wickramaratne P. J., Wittchen H., Yeh E. K. Cross-national epidemiology of major depression and bipolar disorder // JAMA. – 1996. – Vol. 276, No. 4. – P. 293–299.
  • 8. Levola J., Aalto M., Holopainen A., Cieza A., Pitkänen T. Health-related quality of life in alcohol dependence: a systematic literature review with a specific focus on the role of depression and other psychopathology // Nord J Psychiatry. – 2014. – Vol. 68, No. 6. – P. 369–384.
  • 9. Saatcioglu O., Yapici A., Cakmak D. Quality of life, depression and anxiety in alcohol dependence // Drug and Alcohol Review. – 2008. – Vol. 27, No. 1. – P. 83–90.
  • 10. Cornelius J.R., Salloum I.M., Mezzich J., Cornelius M.D., Fabrega H. Jr., Ehler J.G., Ulrich R.F., Thase M.E., Mann J.J. Disproportionate suicidality in patients with comorbid major depression and alcoholism // Am J Psychiatry. – 1995. – Vol. 152, Iss. 3. – P. 358–364.
  • 11. Sher L., Oquendo M.A., Galfalvy H.C., Grunebaum M.F., Burke A.K., Zalsman G., Mann J.J. The relationship of aggression to suicidal behavior in depressed patients with a history of alcoholism // Addict Behav. – 2005. – Vol. 30, Iss. 6. – P. 1144–1153.
  • 12. Forty L., Smith D., Jones L., Jones I., Caesar S., Cooper C., Fraser C., Gordon-Smith K., Hyde S., Farmer A., McGuffin P., Craddock N. Clinical differences between bipolar and unipolar depression // The British Journal of Psychiatry. – 2008. – Vol. 192, No. 5. – P. 388–389.
  • 13. Pringuey D., Cherikh F., Lunacek S., Giordana B., Fakra E., Belzeaux R., Adida M., Azorin J.M. Comorbidity of affective disorders and alcohol use disorder // L'Encéphale. – 2014. – Vol. 40, No. 3. – P. 3–7.
  • 14. Schomerus G., Lucht M., Holzinger A., Matschinger H., Carta M.G., Angermeyer M.C. The Stigma of alcohol dependence compared with other mental disorders: a review of population studies // Alcohol Alcohol. – 2011. – Vol. 46, No. 2. – P. 105–112.
  • 15. Boden J.M., Fergusson D.M. Alcohol and depression // Addiction. – 2011. – Vol. 106, Iss. 5. – P. 906–914.
  • 16. Gilman S.E., Abraham H.D. A longitudinal study of the order of onset of alcohol dependence and major depression // Drug Alcohol Depend. – 2001. – Vol. 63, Iss. 3. – P. 277–286.
  • 17. Al'tshuler V. B. Patologicheskoe vlechenie k alkogolyu. – M.: Imidzh, 1994. – C. 34–37.
  • 18. Mosolov S.N. Sovremennye biologicheskie gipotezy rekurrentnoi depressii (obzor) // Zhurnal nevrologii i psikhiatrii im. C.C. Korsakova. – 2012. – T. 112, № 11–2. – S. 29–40.
  • 19. Nikolishin A.E., Gofman A.G., Kibitov A.O. Alkogol'naya zavisimost' i depressiya: dofaminovaya neiromediatsiya kak klyuch k izucheniyu komorbidnosti // Narkologiya. – 2016. – №. 8. – S. 80–87.
  • 20. Meliksetyan A.S. Rol' faktorov, sposobstvuyushchikh razvitiyu retsidivov khronicheskogo alkogolizma u bol'nykh s korotkimi i dlitel'nymi remissiyami Narkologiya. – 2011. – T. 10, №. 1(109). – S. 75–81.
  • 21. Cleare A.J., Lena J.R. Biological Models of Unipolar Depression // The Wiley-Blackwell Handbook of Mood Disorders. – Wiley-Blackwell, 2013. – P. 39–55.
  • 22. Hasin D.S., Grant B.F. Major depression in 6050 former drinkers: association with past alcohol dependence // Archives of General Psychiatry. – 2002. – Vol. 59, No. 9. – P. 794–800.
  • 23. Fergusson D.M., Boden J.M., Horwood L.J. Tests of causal links between alcohol abuse or dependence and major depression // Archives of General Psychiatry. – 2009. – Vol. 66, No. 3. – P. 260–266.
  • 24. Boschloo L., Vogelzangs N., van den Brink W., Smit J.H., Veltman D.J., Beekman A.T., Penninx B.W. Alcohol use disorders and the course of depressive and anxiety disorders // Br J Psychiatry. – 2012. – Vol. 200, No. 6. – P. 476–484.
  • 25. Gofman A.G., Oife I.A. Alkogolizm i endogennye depressii // Depressii i komorbidnye rasstroistva: monografiya / pod red. prof. A. B. Smulevicha. – M., 1997. – C. 124–136.
  • 26. Gofman A.G. Endogennye depressivnye sostoyaniya i zloupotreblenie alkogolem // Voprosy narkologii. – 2014. – № 3. – S. 120–126.
  • 27. Brady K.T., Verduin M.L., Tolliver B.K. Treatment of patients comorbid for addiction and other psychiatric disorders // Curr Psychiatry Rep. – 2007. – Vol. 9, No. 5. – P. 374–380.
  • 28. Bienvenu O.J., Davydowa D.S., Kendler K.S. Psychiatric “diseases” versus behavioral disorders and degree of genetic influence // Psychol Med. – 2011. – Vol. 41, Iss. 1. – P. 33–40.
  • 29. Ducci F., Goldman D. Genetic approaches to addiction: genes and alcohol // Addiction. – 2008. – Vol. 103, Iss. 9 – P. 1414–1428.
  • 30. Kertes D.A., Kalsi G., Prescott C.A., Kuo P.H., Patterson D.G., Walsh D., Kendler K.S., Riley B.P. Neurotransmitter and neuromodulator genes associated with a history of depressive symptoms in individuals with alcohol dependence // Alcohol Clin Exp Res. – 2011. – Vol. 35, Iss. 3. – P. 496–505.
  • 31. Kalow W., Tang B.K., Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research // Pharmacogenetics. – 1998. – Vol. 8, No. 4. – P. 283–289.
  • 32. Kibitov A.O., Ivashchenko D.V., Sychev D.A. Farmakogeneticheskii podkhod k povysheniyu effektivnosti i bezopasnosti antipsikhoticheskoi farmakoterapii shizofrenii // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2017. – № 1. – S. 2–13.
  • 33. Crettol S., de Leon J., Hiemke C., Eap C.B. Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine // Clin Pharmacol Ther. – 2014. – Vol. 95, No. 3. – P. 254–257.
  • 34. Krylov E.N. Depressivnye rasstroistva u bol'nykh alkogol'noi zavisimost'yu // Narkologiya. – 2004. – T. 3, №. 4. – S. 42–49.
  • 35. Almeida-Filho N., Lessa I., Magalhaes L., Arauho M.J., Aquino E., de Jesus M.J. Co-occurrence patterns of anxiety, depression and alcohol use disorders // European Archives of Psychiatry and Clinical Neuroscience. – 2007. – Vol. 257, Iss. 7. – P. 423–431.
  • 36. Amato L., Minozzi S., Vecchi S., Davoli M. Benzodiazepines for alcohol withdrawal // Cochrane Database Syst Rev. – 2010. – Iss. 3, Art. No. CD005063.
  • 37. Schaefer T.J., Hafner J.W. Are benzodiazepines effective for alcohol withdrawal? // Ann Emerg Med. – 2013. – Vol. 62, Iss. 1. – P. 34–35.
  • 38. Shatsberg A.F., Koil D.O., DeBattista Ch. Rukovodstvo po klinicheskoi psikhofarmakologii / per. s angl., pod obshch. red. akad. Smulevicha A.B., prof. Ivanova S.V. – M.: MEDpress-inform, 2013. – S. 473–479.
  • 39. Minozzi S., Amato L., Vecchi S., Davoli M. Anticonvulsants for alcohol withdrawal // Cochrane Database Syst Rev. – 2010 – Iss. 3, Art. No. CD005064.
  • 40. Griffin C.E., Kaye A.M., Bueno F.R., Kaye A.D. Benzodiazepine pharmacology and central nervous system–mediated effects // Ochsner J. – 2013. – Vol. 13, No. 2. – P. 214–223.
  • 41. Spina E., Pisani F., Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update // Clin Pharmacokinet. – 1996. – Vol. 31, No. 3. – 198–214.
  • 42. Klinicheskaya farmakologiya / pod red. V.G. Kukesa / M: GEOTAR-Media, 2004. – S. 759–771.
  • 43. Kishi T., Sevy S., Chekuri R., Correll C.U. Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials // J Clin Psychiatry. – 2013. – Vol. 74, No. 7. – P. 642–654.
  • 44. Mayo-Smith M.F., Beecher L.H., Fischer T.L., Gorelick D.A., Guillaume J.L., Hill A., Jara G., Kasser C., Melbourne J. Management of alcohol withdrawal delirium. An evidence-based practice guideline // Arch Intern Med. – 2004. – Vol. 164, No. 13. – P. 1405–1412.
  • 45. Grosshans M., Mutschler J., Luderer M., Mann K., Kiefer F. Agomelatine Is Effective in Reducing Insomnia in Abstinent Alcohol-Dependent Patients // Clin Neuropharmacol. – 2014. – Vol. 37, No. 1. – P. 6–8.
  • 46. Kolla B.P., Mansukhani M.P., Schneekloth T. Pharmacological treatment of insomnia in alcohol recovery: a systematic review // Alcohol Alcohol. – 2011. – Vol. 46, No. 5. – P. 578–585.
  • 47. DeVido J.J, Weiss R.D. Treatment of the Depressed Alcoholic Patient // Curr Psychiatry Rep. – 2012. –Vol. 14, No. 6. – P. 610–618.
  • 48. Krupitskii E.M., Rudenko A.A., Tsoi M.V., Neznanova O.N., Burakov A.M., Slavina T.Yu., Grinenko A.Ya., Zvartau E.E., Flanneri B., Krebaum S. Fenomenologiya patologicheskogo vlecheniya k alkogolyu u bol'nykh alkogolizmom v remissii: svyaz' s retsidivom zabolevaniya // Voprosy narkologii. – 2003. – № 6. – S. 15–19.
  • 49. Kostyukova E.G., Mosolov S.N. Differentsirovannyi podkhod k primeneniyu antidepressantov // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2013. – № 3. – S. 2–10.
  • 50. Pettinati H.M. Antidepressant treatment of co-occurring depression and alcohol dependence // Biol Psychiatry. – 2004. – Vol. 56, Iss. 10. – P. 785–792.
  • 51. MacQueen G., Born L., Steiner M. The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders // CNS Drug Rev. – 2001. – Vol. 7, Iss. 1. – P. 1–24.
  • 52. Owens M.J., Knight D.L., Nemeroff C.B. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine // Biol Psychiatry. – 2001. – Vol. 50, Iss. 5. – P. 345–350.
  • 53. Anokhina I.P. Alkogolizm i depressiya – vzaimosvyaz' biologicheskikh mekhanizmov // Rossiiskikh psikhiatricheskii zhurnal. – 1998. - № 6. – S. 30–33.
  • 54. Martin-Soelch C. Is depression associated with dysfunction of the central reward system? // Biochem Soc Trans. – 2009. – Vol. 37, Iss. 1. – P. 313–317.
  • 55. Proulx C.D., Hikosaka O., Malinow R. Reward processing by the lateral habenula in normal and depressive behaviors // Nature Neuroscience. – 2014. – Vol. 17. – P. 1146–1152.
  • 56. Whitton A.E., Treadway M.T., Pizzagalli D.A. Reward processing dysfunction in major depression, bipolar disorder and schizophrenia // Curr Opin Psychiatry. – 2015. – Vol. 28, No. 1. – P. 7–12.
  • 57. Moak D.H., Anton R.F., Latham P.K., Voronin K.E., Waid R.L., Durazo-Arvizu R. Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial // J Clin Psychopharmacol. – 2003. – Vol. 23, Iss. 6. – P. 553–562.
  • 58. Pettinati H.M., Oslin D.W., Kampman K.M., Dundon W.D., Xie H., Gallis T.L., Dackis C.A., O'Brien C.P. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence // Am J Psychiatry. – 2010. – Vol. 167, Iss. 6. – P. 668–675.
  • 59. Kranzler H.R., Armeli S., Tennen H., Covault J., Feinn R., Arias A.J., Pettinati H., Oncken C. A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype // J Clin Psychopharmacol. – 2011. – Vol. 31, No. 1. – P. 22–30.
  • 60. Kranzler H.R., Armeli S., Tennen H. Post-treatment outcomes in a double-blind, randomized trial of sertraline for alcohol dependence // Alcohol Clin Exp Res. – 2012. – Vol. 36, Iss. 4. – P. 739–744.
  • 61. Cornelius J.R., Salloum I.M., Ehler J.G., Jarrett P.J., Cornelius M.D., Perel J.M., Thase M.E., Black A. Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial // Arch Gen Psychiatry. – 1997. – Vol. 54, No. 8. – P. 700–705.
  • 62. Cornelius J.R., Bukstein O.G., Wood D.S., Kirisci L., Douaihy A., Clark D.B. Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder // Addict Behav. – 2009. – Vol. 34, Iss. 10. – P. 905–909.
  • 63. Kranzler H.R., Burleson J.A., Korner P., Del Boca F.K., Bohn M.J., Brown J., Liebowitz N. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics // Am J Psychiatry. – 1995. – Vol. 152, Iss. 3 – P. 391–397.
  • 64. Anokhina I.P. Osnovnye biologicheskie mekhanizmy zavisimosti ot psikhoaktivnykh veshchestv // Voprosy narkologii. – 2013. – № 6. – S. 40–59.
  • 65. Koch S., Perry K.W., Nelson D.L., Conway R.G., Threlkeld P.G., Bymaster F.P. R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study // Neuropsychopharmacology. – 2002. – Vol. 27, No. 6. – P. 949–959.
  • 66. Miguelez C., Fernandez-Aedo I., Torrecilla M., Grandoso L., Ugedo L. α2-Adrenoceptors mediate the acute inhibitory effect of fluoxetine on locus coeruleus noradrenergic neurons // Neuropharmacology. – 2009. – Vol. 56, Iss. 6–7. – P. 1068–1073.
  • 67. Pälvimäki E.P., Roth B.L., Majasuo H., Laakso A., Kuoppamäki M., Syvälahti E., Hietala J. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2C receptor // Psychopharmacology (Berl). – 1996. – Vol. 126, Iss. 3. – P. 234–240.
  • 68. Cipriani A., Santilli C., Furukawa T.A., Signoretti A., Nakagawa A., McGuire H., Churchill R., Barbui C. Escitalopram versus other antidepressive agents for depression // Cochrane Database Syst Rev. – 2009. – Iss. 2, Art. No. CD006532.
  • 69. Ramsberg J., Asseburg C., Henriksson M. Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model // PLoS One. – 2012. – Vol. 7, Iss. 8.
  • 70. Muhonen L.H., Lahti J., Alho H., Lönnqvist J., Haukka J., Saarikoski S.T. Serotonin transporter polymorphism as a predictor for escitalopram treatment of major depressive disorder comorbid with alcohol dependence // Psychiatry Res. – 2011. – Vol. 186, Iss. 1. – P. 53–57.
  • 71. Muhonen L.H., Lönnqvist J., Juva K., Alho H. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence // J Clin Psychiatry. – 2008. – Vol. 69, Iss. 3. – P. 392–399.
  • 72. Muhonen L.H., Lönnqvist J., Lahti J., Alho H. Age at onset of first depressive episode as a predictor for escitalopram treatment of major depression comorbid with alcohol dependence // Psychiatry Res. – 2009. – Vol. 167, Iss. 1–2. – P. 115–122.
  • 73. Altintoprak A.E., Zorlu N., Coskunol H., Akdeniz F., Kitapcioglu G. Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: a randomized, double-blind study // Hum Psychopharmacol. – 2008. – Vol. 23, No. 4. – P. 313–319.
  • 74. Donoghue K., Elzerbi C., Saunders R., Whittington C., Pilling S., Drummond C. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis // Addiction. – 2015. – Vol. 110, Iss. 6. – P. 920–930.
  • 75. Jørgensen C.H., Pedersen B., Tønnesen H. The efficacy of disulfiram for the treatment of alcohol use disorder // Alcohol Clin Exp Res. – 2011. – Vol. 35, Iss. 10. – P. 1749–1758.
  • 76. Rösner S., Hackl-Herrwerth A., Leucht S., Lehert P., Vecchi S., Soyka M. Acamprosate for alcohol dependence // Cochrane Database Syst Rev. – 2010. – Iss. 9, Art. No. CD004332.
  • 77. Streeton C., Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials // Alcohol Alcohol. – 2001. – Vol. 36, No. 6. – P. 544–552.
  • 78. Goldstein M., Anagnoste B., Lauber E., Mckeregham M.R. Inhibition of dopamine-beta-hydroxylase by disulfiram // Life Sci (1962). – 1964. – Vol. 3, No. 7. – P. 763–767.
  • 79. Petrakis I.L., Carroll K.M., Nich C, Gordon L.T., McCance-Katz E.F., Frankforter T., Rounsaville B.J. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts // Addiction. – 2000. – Vol. 95, Iss. 2. – P. 219–228.
  • 80. Arias A.J., Gelernter J., Gueorguieva R., Ralevski E., Petrakis I.L. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans // Am J Addict. – 2014. – Vol. 23, Iss. 3. – P. 288–293.
  • 81. Haile C.N., Kosten T.R., Kosten T.A. Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine // Am J Drug Alcohol Abuse. – 2009. – Vol. 35, No. 3. – P. 161–177.
  • 82. Krupitskii E.M. Primenenie farmakologicheskikh sredstv dlya stabilizatsii remissii i profilaktiki retsidivov pri alkogolizme: zarubezhnye issledovaniya // Voprosy narkologii. – 2003. – № 1. – S. 51–61.
  • 83. Dean A.J., Saunders J.B., Jones R.T., Young R.M., Connor J.P., Lawford B.R. Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence // J Psychiatry Neurosci. – 2006. – Vol. 31, No. 1. – P. 38–45.
  • 84. Brown N., Panksepp J. Low-dose naltrexone for disease prevention and quality of life // Med Hypotheses. – 2009. – Vol. 72, Iss. 3. – P. 333–337.
  • 85. Mischoulon D., Hylek L., Yeung A.S., Clain A.J., Baer L., Cusin C., Ionescu D.F., Alpert J.E., Soskin D.P., Fava M. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants // J Affect Disord. – 2017. – Vol. 208. – P. 6–14.
  • 86. Kranzler H.R., Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis // Alcohol Clin Exp Res. – 2001. – Vol. 25, No. 9. – P. 1335–1341.
  • 87. Skinner M.D., Lahmek P., Pham H., Aubin H.J. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis // PLoS One. – 2014. – Vol. 9, Iss. 2.
  • 88. Farren C.K., Scimeca M., Wu R., Malley S.O. A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence // Drug Alcohol Depend. – 2009. – Vol. 99, Iss. 1–3. – P. 317–321.
  • 89. Witte J., Bentley K., Evins A.E., Clain A.J., Baer L., Pedrelli P., Fava M., Mischoulon D. A randomized, controlled, pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder // J Clin Psychopharmacol. – 2012. – Vol. 32, No. 6. – P. 787–796.
  • 90. Adamson S.J., Sellman J.D., Foulds J.A., Frampton C.M., Deering D., Dunn A., Berks J., Nixon L., Cape G. A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression // J Clin Psychopharmacol. – 2015. – Vol. 35, No. 2. – P. 143–149.
  • 91. Stella L., Addolorato G., Rinaldi B., Capuano A., Berrino L., Rossi F., Maione S. An open randomized study of the treatment of escitalopram alone and combined with gamma-hydroxybutyric acid and naltrexone in alcoholic patients // Pharmacol Res. – 2008. – Vol. 57, Iss. 4. – P. 312–317.
  • 92. Kenna G.A., Zywiak W.H., McGeary J.E., Leggio L., McGeary C., Wang S., Grenga A., Swift R.M. A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline // Alcohol Clin Exp Res. – 2009. – Vol. 33, No. 2. – P. 315–323.
  • 93. Kenna G.A., Zywiak W.H., Swift R.M., McGeary J.E., Clifford J.S., Shoaff J.R., Fricchione S., Brickley M., Beaucage K., Haass-Koffler C.L., Leggio L. Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: exploratory findings // Alcohol. – 2014. – Vol. 48, No. 6. – P. 515–522.
  • 94. Kranzler H.R., Armeli S., Tennen H., Covault J. 5-HTTLPR genotype and daily negative mood moderate the effects of sertraline on drinking intensity // Addict Biol. – 2013. – Vol. 18, No. 6. – P. 1024–1031.
  • 95. Arbaizar B., Diersen-Sotos T., Gómez-Acebo I., Llorca J. Topiramate in the treatment of alcohol dependence: a meta-analysis // Actas Esp Psiquiatr. – 2010. – Vol. 38, No. 1. – P. 8–12.
  • 96. Blodgett J.C., Del Re A.C., Maisel N.C., Finney J.W. A meta-analysis of topiramate's effects for individuals with alcohol use disorders // Alcohol Clin Exp Res. – 2014. – Vol. 38, No. 6. – P. 1481–1488.
  • 97. Knapp C.M., Ciraulo D.A., Sarid-Segal O., Richardson M.A., Devine E., Streeter C.C., Oscar-Berman M., Surprise C., Colaneri L., Putnam M., Waters M., Richambault C. Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders // J Clin Psychopharmacol. – 2015. – Vol. 35, No. 1. – P. 34–42.
  • 98. Leung J.G., Hall-Flavin D., Nelson S., Schmidt K.A., Schak K.M. The role of gabapentin in the management of alcohol withdrawal and dependence // Ann Pharmacother. – 2015. – Vol. 49, Iss. 8. – P. 897–906.
  • 99. Pani P.P., Trogu E., Pacini M., Maremmani I. Anticonvulsants for alcohol dependence // Cochrane Database Syst Rev. – 2014. – Iss. 2, Art. No. CD008544.
  • 100. Vein A.M., Mosolov S.N. Antikonvul'santy v psikhiatricheskoi i nevrologicheskoi praktike // SPb: Meditsinskoe informatsionnoe agentstvo, 1994.
  • 101. Kibitov A.O. Farmakogenetika boleznei zavisimosti ot psikhoaktivnykh veshchestv // Narkologiya. – 2015. – № 11. – S. 61–74.
  • 102. Cho S.B., Aliev F., Clark S.L., Adkins A.E., Edenberg H.J., Bucholz K.K., Porjesz B., Dick D.M. Using Patterns of Genetic Association to Elucidate Shared Genetic Etiologies Across Psychiatric Disorders // Behav Genet. – 2017. – Vol. 47, Iss. 4. – P. 405–415.
  • 103. Edwards A.C., Aliev F., Bierut L.J., Bucholz K.K., Edenberg H., Hesselbrock V., Kramer J., Kuperman S., Nurnberger J.I., Schuckit M.A., Porjesz B., Dick D.M. Genome-wide association study of comorbid depressive syndrome and alcohol dependence // Psychiatr Genet. – 2012. – Vol. 22, No. 1. – P. 31–41.
  • 104. Enoch M.A., Gorodetsky E., Hodgkinson C., Roy A., Goldman D. Functional genetic variants that increase synaptic serotonin and 5-HT3 receptor sensitivity predict alcohol and drug dependence // Mol Psychiatry. – 2011. – Vol. 16, No. 11. – P. 1139–1146.
  • 105. Seneviratne C., Franklin J., Beckett K., Ma J.Z., Ait-Daoud N., Payne T.J., Johnson B.A., Li M.D. Association, interaction, and replication analysis of genes encoding serotonin transporter and 5-HT3 receptor subunits A and B in alcohol dependence // Hum Genet. – 2013. – Vol. 132, No. 10. – P. 1165–1176.
  • 106. Patriquin M.A., Bauer I.E., Soares J.C., Graham D.P., Nielsen D.A. Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system // Psychiatr Genet. – 2015. – Vol. 25, No. 5. – P. 181–193.
  • 107. Table of Pharmacogenomic Biomarkers in Drug Labeling. // Food and Drug Administration. – URL: http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/ Pharmacogenetics/ucm083378.htm (data obrashcheniya: 30.06.2017).
  • 108. Baker A.L., Thornton L.K., Hiles S., Hides L., Lubman D.I. Psychological interventions for alcohol misuse among people with co-occurring depression or anxiety disorders: a systematic review // J Affect Disord. – 2012. – Vol. 139, Iss. 3. – P. 217–229.
  • 109. Thapinta D., Skulphan S., Kittrattanapaiboon P. Brief cognitive behavioral therapy for depression among patients with alcohol dependence in Thailand // Issues Ment Health Nurs. – 2014. – Vol. 35, No. 9. – P. 689–693.
  • 110. Riper H., Andersson G., Hunter S.B., de Wit J., Berking M., Cuijpers P. Treatment of comorbid alcohol use disorders and depression with cognitive-behavioural therapy and motivational interviewing: a meta-analysis // Addiction. – 2014. – Vol. 109, No. 3. – P. 394–406.